Vannabouathong Christopher, Del Fabbro Gina, Sales Brendan, Smith Christopher, Li Chuan Silvia, Yardley Darryl, Bhandari Mohit, Petrisor Bradley A
1 Burlington, Ontario, Canada.
Foot Ankle Int. 2018 Oct;39(10):1141-1150. doi: 10.1177/1071100718779375. Epub 2018 Jun 18.
Intra-articular (IA) injections are commonly used to treat knee arthritis pain; however, whether their efficacy generalizes to ankle arthritis remains debatable. We aimed to evaluate the evidence for IA therapies in the management of this patient population.
We performed a literature search for observational and randomized controlled trials (RCTs). Treatments included corticosteroids (CS), hyaluronic acid (HA), platelet-rich plasma (PRP), and mesenchymal stem cells (MSC). We extracted study details, patient demographics, treatment characteristics, efficacy outcomes, and safety. When feasible, data from RCTs were meta-analyzed using a random-effects model and 95% confidence intervals (CIs) were calculated. A P value <.05 was considered statistically significant.
We identified 27 studies (1085 patients). Ankle OA, rheumatoid arthritis (RA), and hemophilic arthropathy populations were examined. The majority of studies were observational (20 studies); the only RCTs were those evaluating HA. Case series demonstrated favorable results in terms of symptomatic relief with CS, HA, PRP, and MSC injections; however, the effects of CS may only be short term and the evidence on MSCs was limited to 1 study with 6 ankle OA patients. Pooled results (3 RCTs, 109 patients) suggested significantly improved Ankle Osteoarthritis Scale scores with HA over saline at 6 months, with a mean difference of 12.47 points (95% CI 1.18-23.77, P = .03).
Evidence from small trials favors HA and PRP injections for the treatment of pain associated with ankle osteoarthritis. However, the relative efficacy of all injectable therapies is far from definitive and warrants further high-quality comparative trials.
Level III, systematic review.
关节内(IA)注射常用于治疗膝关节关节炎疼痛;然而,其疗效是否适用于踝关节关节炎仍存在争议。我们旨在评估IA疗法在该患者群体管理中的证据。
我们对观察性研究和随机对照试验(RCT)进行了文献检索。治疗方法包括皮质类固醇(CS)、透明质酸(HA)、富血小板血浆(PRP)和间充质干细胞(MSC)。我们提取了研究细节、患者人口统计学信息、治疗特征、疗效结果和安全性。在可行的情况下,使用随机效应模型对RCT的数据进行荟萃分析,并计算95%置信区间(CI)。P值<.05被认为具有统计学意义。
我们确定了27项研究(1085例患者)。研究对象包括踝关节骨关节炎(OA)、类风湿关节炎(RA)和血友病性关节病患者群体。大多数研究为观察性研究(20项);唯一的RCT是评估HA的研究。病例系列显示,CS、HA、PRP和MSC注射在症状缓解方面取得了良好效果;然而,CS的效果可能只是短期的,关于MSC的证据仅限于1项对6例踝关节OA患者的研究。汇总结果(3项RCT,109例患者)表明,在6个月时,HA治疗组的踝关节骨关节炎量表评分显著高于生理盐水对照组,平均差异为12.47分(95%CI 1.18 - 23.77,P =.03)。
小规模试验的证据支持HA和PRP注射用于治疗与踝关节骨关节炎相关的疼痛。然而,所有注射疗法的相对疗效远未明确,需要进一步进行高质量的对比试验。
三级,系统评价。